Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Incretin incrementals

June 22nd 2014

At the 2014 American Diabetes Association meeting, there were many presentations on GLP-1RA injectable treatments.

Data were presented on use of liraglutide in moderate renal failure (eGFR 30-60 mL/min: stage 3 chronic kidney). In keeping with its known routes of metabolism and elimination, there were no adverse effects on renal function, nor reduction in efficacy.

Lixisenatide was effective irrespective of the starting beta-cell function of patients (assessed by HOMA-b index) and shown to have less impact on pulse than liraglutide, although this may well reflect its shorter duration of effect.

Results were presented on two new once weekly GLP-1 injectable therapies. The HARMONY trial programme assessing albiglutide shows it to be well tolerated although interestingly the main GI side-effect was diarrheoa (rather than nausea/vomiting). Once weekly dulogletide showed non-inferiority to liraglutide in terms of HbA1c reduction (the first GLP-1RA to achieve this) but didn’t achieve the same weight reduction.

Perhaps the least incremental of advances was effective lowering of HbA1c in poorly controlled patients by exenatide administered via the ITCA650 implantable mini-pump, a once yearly treatment….

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaBoehringer IngelheimNovo NordiskNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAbout Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership